Insider Buy/Sell Details for the Biotechnology Industry — Last 30 Days
Ratio0.2:1
Daily Buy & Sell Volume
Transactions (924)
HALOZYME THERAPEUTICS, INC. (HALO)
Posard Matthew L. — Director
Shares
4,000
Price
$108.99
Total Value
$435.96K
Shares Held After
58,839
% of Holdings
6.4%
HALOZYME THERAPEUTICS, INC. (HALO)
Posard Matthew L. — Director
Shares
8,896
Price
$108.04
Total Value
$961.12K
Shares Held After
62,839
% of Holdings
12.4%
HALOZYME THERAPEUTICS, INC. (HALO)
Posard Matthew L. — Director
Shares
3,000
Price
$106.83
Total Value
$320.48K
Shares Held After
71,735
% of Holdings
4.0%
HALOZYME THERAPEUTICS, INC. (HALO)
Posard Matthew L. — Director
Shares
3,100
Price
$106.13
Total Value
$329.01K
Shares Held After
74,735
% of Holdings
4.0%
TENAX THERAPEUTICS, INC. (TENX)
Doogan Declan — Director
Shares
53,000
Price
$1.92
Total Value
$101.76K
Shares Held After
55,274
% of Holdings
95.9%
Travere Therapeutics, Inc. (TVTX)
Dube Eric M — Director
Shares
96,125
Price
$63.64
Total Value
$6.12M
Shares Held After
432,886
% of Holdings
18.2%
Travere Therapeutics, Inc. (TVTX)
Dube Eric M — Director
Shares
99,716
Price
$63.26
Total Value
$6.31M
Shares Held After
529,011
% of Holdings
15.9%
Travere Therapeutics, Inc. (TVTX)
ROTE WILLIAM E. — Chief Research Officer
Shares
47,746
Price
$63.61
Total Value
$3.04M
Shares Held After
98,197
% of Holdings
32.7%
Travere Therapeutics, Inc. (TVTX)
ROTE WILLIAM E. — Chief Research Officer
Shares
65,104
Price
$63.12
Total Value
$4.11M
Shares Held After
145,943
% of Holdings
30.8%
Travere Therapeutics, Inc. (TVTX)
Heerma Peter — EVP, CHIEF COMMERCIAL OFFICER
Shares
79,113
Price
$63.65
Total Value
$5.04M
Shares Held After
117,066
% of Holdings
40.3%
Travere Therapeutics, Inc. (TVTX)
Heerma Peter — EVP, CHIEF COMMERCIAL OFFICER
Shares
93,604
Price
$63.25
Total Value
$5.92M
Shares Held After
196,179
% of Holdings
32.3%
Inhibrx Biosciences, Inc. (INBX)
Kayyem Jon Faiz — Director
Shares
5,000
Price
$100.00
Total Value
$500.00K
Shares Held After
429,360
% of Holdings
1.2%
Upstream Bio, Inc. (UPB)
Deykin Aaron — Chief Medical Officer
Shares
895
Price
$5.49
Total Value
$4.91K
Shares Held After
32,302
% of Holdings
2.7%
Upstream Bio, Inc. (UPB)
Houghton Adam — Chief Business Officer
Shares
700
Price
$5.49
Total Value
$3.84K
Shares Held After
22,901
% of Holdings
3.0%
Upstream Bio, Inc. (UPB)
Sutherland Everett Rand — Director
Shares
2,095
Price
$5.49
Total Value
$11.50K
Shares Held After
68,717
% of Holdings
3.0%
Upstream Bio, Inc. (UPB)
GRAY MICHAEL — CFO and COO
Shares
853
Price
$5.49
Total Value
$4.68K
Shares Held After
27,942
% of Holdings
3.0%
Upstream Bio, Inc. (UPB)
Ambrose Allison — General Counsel
Shares
485
Price
$5.49
Total Value
$2.66K
Shares Held After
15,563
% of Holdings
3.0%
AIM ImmunoTech Inc. (AIM)
Equels Thomas K — Director
Shares
11,000
Price
$0.21
Total Value
$2.31K
Shares Held After
102,822
% of Holdings
10.7%
Adagene Inc. (ADAG)
Luo Peter — Director
Shares
20,290
Price
$3.15
Total Value
$63.98K
Shares Held After
88,535
% of Holdings
22.9%
InMed Pharmaceuticals Inc. (INM)
ADAR1 Capital Management, LLC — 10% Owner
Shares
8,340
Price
$1.29
Total Value
$10.75K
Shares Held After
892,101
% of Holdings
0.9%
BioNTech SE (BNTX)
Sahin Ugur — Chief Executive Officer
Shares
15,000
Price
$96.09
Total Value
$1.44M
Shares Held After
553,209
% of Holdings
2.6%
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
He Junli — Director
Shares
6,725
Price
$2.15
Total Value
$14.46K
Shares Held After
1,332,930
% of Holdings
0.5%
Trevi Therapeutics, Inc. (TRVI)
Heffernan Michael Thomas — Director
Shares
100
Price
$15.88
Total Value
$1.59K
Shares Held After
6,351
% of Holdings
1.6%
Trevi Therapeutics, Inc. (TRVI)
Heffernan Michael Thomas — Director
Shares
20,952
Price
$15.09
Total Value
$316.17K
Shares Held After
6,451
% of Holdings
76.5%
Trevi Therapeutics, Inc. (TRVI)
Heffernan Michael Thomas — Director
Shares
100
Price
$15.88
Total Value
$1.59K
Shares Held After
6,351
% of Holdings
1.6%
Trevi Therapeutics, Inc. (TRVI)
Heffernan Michael Thomas — Director
Shares
18,321
Price
$15.09
Total Value
$276.46K
Shares Held After
6,451
% of Holdings
74.0%
Vera Therapeutics, Inc. (VERA)
Fordyce Marshall — Director
Shares
18,500
Price
$37.00
Total Value
$684.50K
Shares Held After
235,244
% of Holdings
7.3%
CG Oncology, Inc. (CGON)
POST LEONARD E — Director
Shares
1,000
Price
$72.98
Total Value
$72.98K
Shares Held After
0
% of Holdings
100.0%
Travere Therapeutics, Inc. (TVTX)
Inrig Jula — EVP, Head of R&D&CMO
Shares
400
Price
$65.31
Total Value
$26.12K
Shares Held After
100,491
% of Holdings
0.4%
Travere Therapeutics, Inc. (TVTX)
Inrig Jula — EVP, Head of R&D&CMO
Shares
1,600
Price
$63.69
Total Value
$101.90K
Shares Held After
100,891
% of Holdings
1.6%
Travere Therapeutics, Inc. (TVTX)
Inrig Jula — EVP, Head of R&D&CMO
Shares
17,284
Price
$62.62
Total Value
$1.08M
Shares Held After
102,491
% of Holdings
14.4%
Travere Therapeutics, Inc. (TVTX)
Inrig Jula — EVP, Head of R&D&CMO
Shares
25,390
Price
$62.02
Total Value
$1.57M
Shares Held After
119,775
% of Holdings
17.5%
Travere Therapeutics, Inc. (TVTX)
Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER
Shares
300
Price
$63.66
Total Value
$19.10K
Shares Held After
42,353
% of Holdings
0.7%
Travere Therapeutics, Inc. (TVTX)
Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER
Shares
800
Price
$62.85
Total Value
$50.28K
Shares Held After
42,653
% of Holdings
1.8%
Travere Therapeutics, Inc. (TVTX)
Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER
Shares
4,275
Price
$62.13
Total Value
$265.63K
Shares Held After
43,453
% of Holdings
9.0%
Travere Therapeutics, Inc. (TVTX)
Cline Christopher R. — CHIEF FINANCIAL OFFICER
Shares
400
Price
$65.31
Total Value
$26.12K
Shares Held After
87,508
% of Holdings
0.5%
Travere Therapeutics, Inc. (TVTX)
Cline Christopher R. — CHIEF FINANCIAL OFFICER
Shares
1,900
Price
$63.69
Total Value
$121.00K
Shares Held After
87,908
% of Holdings
2.1%
Travere Therapeutics, Inc. (TVTX)
REED ELIZABETH E — Chief Legal Officer and GC
Shares
300
Price
$65.31
Total Value
$19.59K
Shares Held After
105,389
% of Holdings
0.3%
Travere Therapeutics, Inc. (TVTX)
Dube Eric M — Director
Shares
270
Price
$65.31
Total Value
$17.63K
Shares Held After
432,886
% of Holdings
0.1%
Travere Therapeutics, Inc. (TVTX)
Cline Christopher R. — CHIEF FINANCIAL OFFICER
Shares
20,735
Price
$62.61
Total Value
$1.30M
Shares Held After
89,808
% of Holdings
18.8%
Travere Therapeutics, Inc. (TVTX)
Dube Eric M — Director
Shares
3,102
Price
$63.64
Total Value
$197.42K
Shares Held After
433,156
% of Holdings
0.7%
Travere Therapeutics, Inc. (TVTX)
REED ELIZABETH E — Chief Legal Officer and GC
Shares
1,400
Price
$63.69
Total Value
$89.17K
Shares Held After
105,689
% of Holdings
1.3%
Travere Therapeutics, Inc. (TVTX)
Dube Eric M — Director
Shares
28,796
Price
$62.66
Total Value
$1.80M
Shares Held After
436,258
% of Holdings
6.2%
Travere Therapeutics, Inc. (TVTX)
Cline Christopher R. — CHIEF FINANCIAL OFFICER
Shares
27,473
Price
$62.00
Total Value
$1.70M
Shares Held After
110,543
% of Holdings
19.9%
Travere Therapeutics, Inc. (TVTX)
REED ELIZABETH E — Chief Legal Officer and GC
Shares
13,874
Price
$62.63
Total Value
$868.96K
Shares Held After
107,089
% of Holdings
11.5%
Travere Therapeutics, Inc. (TVTX)
Dube Eric M — Director
Shares
63,498
Price
$61.99
Total Value
$3.94M
Shares Held After
465,054
% of Holdings
12.0%
Travere Therapeutics, Inc. (TVTX)
REED ELIZABETH E — Chief Legal Officer and GC
Shares
21,926
Price
$62.03
Total Value
$1.36M
Shares Held After
120,963
% of Holdings
15.3%
Travere Therapeutics, Inc. (TVTX)
ROTE WILLIAM E. — Chief Research Officer
Shares
270
Price
$65.31
Total Value
$17.63K
Shares Held After
98,197
% of Holdings
0.3%
Travere Therapeutics, Inc. (TVTX)
ROTE WILLIAM E. — Chief Research Officer
Shares
3,000
Price
$63.65
Total Value
$190.95K
Shares Held After
98,467
% of Holdings
3.0%
Travere Therapeutics, Inc. (TVTX)
ROTE WILLIAM E. — Chief Research Officer
Shares
29,021
Price
$62.66
Total Value
$1.82M
Shares Held After
101,467
% of Holdings
22.2%
Showing 401–450 of 924 transactions (page 9 of 19)